References
Key articles
Public Health England. Diagnosis of urinary tract infections: quick reference tool for primary care for consultation and local adaptation. May 2020 [internet publication].Full text
European Association of Urology. Guidelines on urological infections. 2023 [internet publication].Full text
National Institute for Health and Care Excellence. Pyelonephritis (acute): antimicrobial prescribing. October 2018 [internet publication].Full text
Reference articles
1. Bergeron MG. Treatment of pyelonephritis in adults. Med Clin North Am. 1995 May;79(3):619-49. Abstract
2. Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician. 2005 Mar 1;71(5):933-42. Abstract
3. Scottish Intercollegiate Guidelines Network. Management of suspected bacterial lower urinary tract infection in adult women. September 2020 [internet publication].Full text
4. Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis. 2007 Aug 1;45(3):273-80. Abstract
5. Geerlings SE. Clinical presentations and epidemiology of urinary tract infections. Microbiol Spectr. 2016 Oct;4(5). Abstract
6. Valera B, Gentil MA, Cabello V, et al. Epidemiology of urinary infections in renal transplant recipients. Transplant Proc. 2006 Oct;38(8):2414-5. Abstract
7. Matuszkiewicz-Rowińska J, Małyszko J, Wieliczko M. Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems. Arch Med Sci. 2015 Mar 16;11(1):67-77.Full text Abstract
8. Scholes D, Hooton TM, Roberts PL, et al. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med. 2005 Jan 4;142(1):20-7. Abstract
9. Manges AR, Johnson JR, Foxman B, et al. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med. 2001 Oct 4;345(14):1007-13. Abstract
10. Johnson JR, Manges AR, O'Bryan TT, et al. A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis. Lancet. 2002 Jun 29;359(9325):2249-51. Abstract
11. Ramchandani M, Manges AR, DebRoy C, et al. Possible animal origin of human-associated, multidrug-resistant, uropathogenic Escherichia coli. Clin Infect Dis. 2005 Jan 15;40(2):251-7. Abstract
12. Nicolle LE; AMMI Canada Guidelines Committee. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol. 2005 Nov;16(6):349-60.Full text Abstract
13. Matthews SJ, Lancaster JW. Urinary tract infections in the elderly population. Am J Geriatr Pharmacother. 2011 Oct;9(5):286-309. Abstract
14. Lane MC, Mobley HL. Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the mammalian kidney. Kidney Int. 2007 Jul;72(1):19-25. Abstract
15. Johnson JR. Microbial virulence determinants and the pathogenesis of urinary tract infection. Infect Dis Clin North Am. 2003 Jun;17(2):261-78. Abstract
16. Guyer DM, Kao JS, Mobley HL. Genomic analysis of a pathogenicity island in uropathogenic Escherichia coli CFT073: distribution of homologous sequences among isolates from patients with pyelonephritis, cystitis, and catheter-associated bacteriuria and from fecal samples. Infect Immun. 1998 Sep;66(9):4411-7.Full text Abstract
17. Hacker J, Blum-Oehler G, Hochhut B, et al. The molecular basis of infectious diseases: pathogenicity islands and other mobile genetic elements: a review. Acta Microbiol Immunol Hung. 2003;50(4):321-30. Abstract
18. Boyko EJ, Fihn SD, Scholes D, et al. Diabetes and the risk of acute urinary tract infections among postmenopausal women. Diabetes Care. 2002 Oct;25(10):1778-83.Full text Abstract
19. Brown JS, Vittinghoff E, Kanaya AM, et al. Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet Gynecol. 2001 Dec;98(6):1045-52. Abstract
20. Pabich WL, Fihn SD, Stamm WE, et al. Prevalence and determinants of vaginal flora alterations in postmenopausal women. J Infect Dis. 2003 Oct 1;188(7):1054-8. Abstract
21. Geerlings SE, Meiland R, van Lith EC, et al. Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells; more in diabetic women than in control subjects. Diabetes Care. 2002 Aug;25(8):1405-9.Full text Abstract
22. Hooton TM, Roberts PL, Stamm WE. Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clin Infect Dis. 1994 Aug;19(2):274-8. Abstract
23. Scholes D, Hooton TM, Roberts PL, et al. Risk factors for recurrent urinary tract infection in young women. J Infect Dis. 2000 Oct;182(4):1177-82.Full text Abstract
24. Gupta K, Stapleton AE, Hooton TM, et al. Inverse association of H2O2-producing lactobacilli and vaginal Escherichia coli colonization in women with recurrent urinary tract infections. J Infect Dis. 1998 Aug;178(2):446-50. Abstract
25. Ki M, Park T, Choi B, et al. The epidemiology of acute pyelonephritis in South Korea, 1997-1999. Am J Epidemiol. 2004 Nov 15;160(10):985-93.Full text Abstract
26. Public Health England; NHS England. Treating your infection: urinary tract infection (UTI). October 2020 [internet publication].Full text
27. Public Health England. Diagnosis of urinary tract infections: quick reference tool for primary care for consultation and local adaptation. May 2020 [internet publication].Full text
28. National Institute for Health and Care Excellence. Sepsis: recognition, diagnosis and early management. September 2017 [internet publication].Full text
29. Nutbeam T, Daniels R; The UK Sepsis Trust. Professional resources: clinical [internet publication].Full text
30. NHS England. Sepsis guidance implementation advice for adults. September 2017 [internet publication].Full text
31. Royal College of Physicians. National early warning score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. December 2017 [internet publication].Full text
32. Academy of Medical Royal Colleges. Statement on the initial antimicrobial treatment of sepsis V2.0. Oct 2022 [internet publication].Full text
33. Colgan R, Williams M, Johnson JR. Diagnosis and treatment of acute pyelonephritis in women. Am Fam Physician. 2011 Sep 1;84(5):519-26.Full text Abstract
34. European Association of Urology. Guidelines on urological infections. 2023 [internet publication].Full text
35. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Oct 2023 [internet publication].Full text
36. National Institute for Health and Care Excellence. Pyelonephritis (acute): antimicrobial prescribing. October 2018 [internet publication].Full text
37. Inada-Kim M. Introducing the suspicion of sepsis insights dashboard. Royal College of Pathologists Bulletin. 2019 Apr;186;109.
38. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009 Dec 2;302(21):2323-9.Full text Abstract
39. Gauer RL. Early recognition and management of sepsis in adults: the first six hours. Am Fam Physician. 2013 Jul 1;88(1):44-53.Full text Abstract
40. Car J. Urinary tract infections in women: diagnosis and management in primary care. BMJ. 2006 Jan 14;332(7533):94-7.Full text Abstract
41. Lee HS, Le J. Urinary tract infections. In: PSAP 2018 book 1: Infectious diseases. Lenexa, KS: ACCP; 2018:7-28.
42. National Institute for Health and Care Excellence. Antenatal care for uncomplicated pregnancies. February 2019 [internet publication].Full text
43. Millar LK, Cox SM. Urinary tract infections complicating pregnancy. Infect Dis Clin North Am. 1997 Mar;11(1):13-26. Abstract
44. Schneeberger C, Geerlings SE, Middleton P, et al. Interventions for preventing recurrent urinary tract infection during pregnancy. Cochrane Database Syst Rev. 2015 Jul 26;(7):CD009279.Full text Abstract
45. European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. March 2019 [internet publication].Full text
46. Medicines and Healthcare products Regulatory Agency. Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects. March 2019 [internet publication].Full text
47. Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015 May 16;385(9981):1949-56. Abstract
48. Pasiechnikov S, Buchok O, Sheremeta R, et al. Empirical treatment in patients with acute obstructive pyelonephritis. Infect Disord Drug Targets. 2015;15(3):163-70. Abstract
49. Park DW, Peck KR, Chung MH, et al. Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial. J Korean Med Sci. 2012 May;27(5):476-83.Full text Abstract
50. Vazquez JA, González Patzán LD, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012 Dec;28(12):1921-31. Abstract
51. Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology. 2008 Jan;71(1):17-22. Abstract
52. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA. 2000 Mar 22-29;283(12):1583-90.Full text Abstract
53. Lee RA, Centor RM, Humphrey LL, et al. Appropriate use of short-course antibiotics in common infections: best practice advice from the American College of Physicians. Ann Intern Med. 2021 Apr 6 [Epub ahead of print].Full text Abstract
54. Eliakim-Raz N, Yahav D, Paul M, et al. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection - 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2013 Oct;68(10):2183-91. Abstract
55. Kyriakidou KG, Rafailidis P, Matthaiou DK, et al. Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials. Clin Ther. 2008 Oct;30(10):1859-68. Abstract
56. Ren H, Li X, Ni ZH, et al. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial. Int Urol Nephrol. 2017 Mar;49(3):499-507.Full text Abstract
57. National Institute for Health and Care Excellence. Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use. August 2015 [internet publication].Full text
58. Public Health England. Antimicrobial stewardship: start smart - then focus. March 2015 [internet publication].Full text
59. Wing DA, Fassett MJ, Getahun D. Acute pyelonephritis in pregnancy: an 18-year retrospective analysis. Am J Obstet Gynecol. 2014 Mar;210(3):219.e1-6.Full text Abstract
60. Gupta R, Verma I, Sharma S, et al. Prevention of tissue injury in an ascending mouse model of chronic pyelonephritis--role of free radical scavengers. Comp Immunol Microbiol Infect Dis. 2004 Jul;27(4):225-34. Abstract
61. Kucuk HF, Bigul SM, Kurt N, et al. Effect of a selective cyclooxygenase-2 inhibitor on renal scarring. Eur Surg Res. 2006;38(5):451-7. Abstract
62. O'Brien VP, Hannan TJ, Nielsen HV, et al. Drug and vaccine development for the treatment and prevention of urinary tract infections. Microbiol Spectr. 2016 Feb;4(1).Full text Abstract
63. Kumar V, Ganguly N, Joshi K, et al. Protective efficacy and immunogenicity of escheria coli K13 diphtheria toxoid conjugate against experimental ascending pyelonephritis. Med Microbiol Immunol. 2005 Aug;194(4):211-7. Abstract
64. Castanheira M, Huband MD, Mendes RE, et al. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Aug 24;61(9):e00567-17. Abstract
65. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018 Feb 27;319(8):788-99.Full text Abstract
66. Cox G, Ejim L, Stogios PJ, et al. Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes. ACS Infect Dis. 2018 Jun 8;4(6):980-7. Abstract
67. Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019 Feb 21;380(8):729-40.Full text Abstract
68. European Medicines Agency. Zemdri: withdrawal of the marketing authorisation application. June 2020 [internet publication].Full text
69. European Medicines Agency. Fetcroja. July 2020 [internet publication].Full text
70. Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018 Dec;18(12):1319-28. Abstract
71. European Medicines Agency. Recarbrio. February 2020 [internet publication].Full text
72. National Institute for Health and Care Excellence. Antimicrobial prescribing: imipenem with cilastatin and relebactam - advisory statement on likely place in therapy. October 2020 [internet publication].Full text
73. Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017 Sep 1;72(9):2616-26.Full text Abstract
74. Glaser AP, Schaeffer AJ. Urinary tract infection and bacteriuria in pregnancy. Urol Clin North Am. 2015 Nov;42(4):547-60. Abstract
Comorbidities Manager reference articles
75. European Association of Urology. Guidelines on urological infections. Mar 2023 [internet publication]Full text
76. Colgan R, Williams M, Johnson JR. Diagnosis and treatment of acute pyelonephritis in women. Am Fam Physician. 2011 Sep 1;84(5):519-26Full text Abstract
77. Hsiao CY, Yang HY, Chang CH, et al. Risk factors for development of septic shock in patients with urinary tract infection. Biomed Res Int. 2015;2015:717094Full text Abstract
78. Hsiao CY, Yang HY, Hsiao MC, et al. Risk factors for development of acute kidney injury in patients with urinary tract infection. PLoS One. 2015 Jul 27;10(7):e0133835Full text Abstract
79. Clifford KM, Dy-Boarman EA, Haase KK, et al. Challenges with diagnosing and managing sepsis in older adults. Expert Rev Anti Infect Ther. 2016;14(2):231-41Full text Abstract
80. Dalhousie University. Using the Clinical Frailty Scale to rapidly assay grades of fitness and frailty. April 2020 [internet publication].Full text
81. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726Full text Abstract
82. McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-39.Full text Abstract
83. Umapathysivam MM, Gunton J, Stranks SN, et al. Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction. Diabetes Care. 2024 Jan 1;47(1):140-3.Full text Abstract
84. Pendlebury ST, Klaus SP, Mather M, et al. Routine cognitive screening in older patients admitted to acute medicine: abbreviated mental test score (AMTS) and subjective memory complaint versus Montreal Cognitive Assessment and IQCODE. Age Ageing. 2015 Oct 13;44(6):1000-5Full text Abstract
85. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972 Nov;1(4):233-8 Abstract
86. Emery A, Wells J, Klaus SP, et al. Underestimation of cognitive impairment in older inpatients by the Abbreviated Mental Test Score versus the Montreal Cognitive Assessment: cross-sectional observational study. Dement Geriatr Cogn Dis Extra. 2020 Sep-Dec;10(3):205-15.Full text Abstract
87. Scottish Intercollegiate Guidelines Network. Risk reduction and management of delirium. Mar 2019 [internet publication].Full text
88. Bellelli G, Morandi A, Davis DH, et al. Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234 hospitalised older people. Age Ageing. 2014 Mar 2;43(4):496-502.Full text Abstract
89. National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and management in hospital and long-term care. Jan 2023 [internet publication].Full text
90. Tieges Z, Maclullich AMJ, Anand A, et al. Diagnostic accuracy of the 4AT for delirium detection in older adults: systematic review and meta-analysis. Age Ageing. 2021 May 5;50(3):733-43.Full text Abstract
91. National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and management in hospital and long-term care. 2023 [internet publication]Full text
92. Zhang XM, Jiao J, Xie XH, et al. The association between frailty and delirium among hospitalized patients: an updated meta-analysis. J Am Med Dir Assoc. 2021 Mar;22(3):527-34. Abstract
93. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. Jun 2018 [internet publication].Full text
94. Bishara D. Managing drugs with anticholinergic activity. Drug Ther Bull. 2023 Sep;61(9):135-9.Full text Abstract
95. Lisibach A, Gallucci G, Benelli V, et al. Evaluation of the association of anticholinergic burden and delirium in older hospitalised patients: a cohort study comparing 19 anticholinergic burden scales. Br J Clin Pharmacol. 2022 Nov;88(11):4915-27.Full text Abstract
96. Smith H, Fligelstone H. Reducing patient and planetary harms from high anticholinergic burden medication. BMJ. 2024 Jan 15;384:e075708.Full text Abstract
97. Gracie TJ, Caufield-Noll C, Wang NY, et al. The association of preoperative frailty and postoperative delirium: a meta-analysis. Anesth Analg. 2021 Aug 1;133(2):314-23.Full text Abstract
98. Liu CY, Gong N, Liu W. The association between preoperative frailty and postoperative delirium: a systematic review and meta-analysis. J Perianesth Nurs. 2022 Feb;37(1):53-62.e1. Abstract
99. White S, Griffiths R, Baxter M, et al. Guidelines for the peri-operative care of people with dementia: guidelines from the Association of Anaesthetists. Anaesthesia. 2019 Jan 11;74(3):357-72Full text Abstract
100. Burton JK, Craig L, Yong SQ, et al. Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2021 Nov 26;(11):CD013307.Full text Abstract
101. Public Health England. Urinary tract infection: diagnostic tools for primary care. October 2020 [internet publication]Full text
102. Medicines and Healthcare products Regulatory Agency. Haloperidol (haldol): reminder of risks when used in elderly patients for the acute treatment of delirium. Dec 2021 [internet publication]Full text
103. Mühlbauer V, Möhler R, Dichter MN, et al. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2021 Dec 17;12(12):CD013304.Full text Abstract
104. Yunusa I, Alsumali A, Garba AE, et al. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open. 2019 Mar 1;2(3):e190828.Full text Abstract
105. Van Leeuwen E, Petrovic M, van Driel ML, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018 Mar 30;3:CD007726.Full text Abstract
106. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010 Nov 9;6(12):681-94 Abstract
107. Elkind MSV, Boehme AK, Smith CJ, et al. Infection as a stroke risk factor and determinant of outcome after stroke. Stroke. 2020 Oct;51(10):3156-68.Full text Abstract
108. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 2000 Oct;31(10):2307-13 Abstract
109. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016 May 4;47(6):e98-e169Full text Abstract
110. Fritz Z, Slowther AM, Perkins GD. Resuscitation policy should focus on the patient, not the decision. BMJ. 2017 Feb 28;356:j813Full text Abstract
111. British Medical Association, the Resuscitation Council (UK) and the Royal College of Nursing. Decisions relating to cardiopulmonary resuscitation. 2016 [internet publication].Full text
112. The National Institute for Health and Care Excellence. Decision making and mental capacity. October 2018 [internet publication]Full text
113. Office of the Public Guardian. Mental Capacity Act: making decisions. Jun 2023 [internet publication]Full text
114. Social Care Institute for Excellence. Independent mental capacity advocate (IMCA). January 2010 [internet publication]Full text
115. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. July 2019 [internet publication].Full text
116. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2024 [internet publication]Full text
117. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004 Jun;125(6):2309-21Full text Abstract
118. Au DH, Curtis JR, Every NR, et al. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest. 2002 Mar;121(3):846-51Full text Abstract
119. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2024 [internet publication].Full text
120. Walters JA, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018 Mar 19;3:CD006897Full text Abstract
121. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. July 2019 [internet publication]Full text
122. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13 Abstract
123. Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011 May;106(5):906-14. Abstract
124. National Institute for Health and Care Excellence. Depression in adults: treatment and management. Jun 2022 [internet publication]Full text
125. Horowitz M, Taylor DM. The Maudsley deprescribing guidelines: antidepressants, benzodiazepines, gabapentinoids and Z-drugs. Chichester: Wiley-Blackwell; 2024.
126. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th edition. Chichester: Wiley-Blackwell; 2021
127. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015 May 12;29(5):459-525Full text Abstract
128. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112-20. Abstract
129. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014 Feb 19;348:g1626 Abstract
130. Nochaiwong S, Ruengorn C, Awiphan R, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med. 2022 Dec;54(1):80-97Full text Abstract
131. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008 Jan 1;27(1):31-40Full text Abstract
132. Flowers L. Nicotine replacement therapy. Am J Psychiatry Resid. 2016 Jun;11(6)4-7Full text
133. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469-94 Abstract
134. Oliveira P, Ribeiro J, Donato H, Madeira N. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry. 2017;16:17Full text Abstract
135. National Institute for Health and Care Excellence. Liaison psychiatry. In: Emergency acute medical care in over 16s: service delivery and organisation. March 2018 [internet publication]Full text
136. National Confidential Enquiry into Patient Outcome and Death (NCEPOD). Treat as one. Bridging the gap between mental and physical healthcare in general hospitals. 2017 [internet publication]Full text
137. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000 Jul 24;160(14):2101-7 Abstract
138. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust. 2009 Apr 6;190(S7):S54-60 Abstract
139. National Institute for Health and Care Excellence. Depression in adults with a chronic physical health problem: recognition and management. October 2009 [internet publication]Full text
140. Prina AM, Cosco TD, Dening T, et al. The association between depressive symptoms in the community, non-psychiatric hospital admission and hospital outcomes: a systematic review. J Psychosom Res. 2015 Jan;78(1):25-33Full text Abstract
141. Archer G, Kuh D, Hotopf M, et al. Association between lifetime affective symptoms and premature mortality. JAMA Psychiatry. 2020 Aug 1;77(8):806-13Full text Abstract
142. Machado MO, Veronese N, Sanches M, et al. The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. BMC Med. 2018 Jul 20;16(1):112Full text Abstract
143. National Institute for Health and Care Excellence. Tobacco: preventing uptake, promoting quitting and treating dependence. Feb 2025 [internet publication].Full text
144. Theodoulou A, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2023 Jun 19;6(6):CD013308Full text Abstract
145. Rigotti NA, Kruse GR, Livingstone-Banks J, et al. Treatment of tobacco smoking: a review. JAMA. 2022 Feb 8;327(6):566-77.Full text Abstract
146. Agrawal S, Evison M, Ananth S, et al. Medical management of inpatients with tobacco dependency. Thorax. 2024 Mar 26;79(suppl 1):3-11.Full text Abstract
147. Lindson N, Theodoulou A, Ordóñez-Mena JM, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst Rev. 2023 Sep 12;9(9):CD015226.Full text Abstract
148. Thomas KH, Dalili MN, López-López JA, et al. Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials. Addiction. 2022 Apr;117(4):861-76.Full text Abstract
149. Livingstone-Banks J, Fanshawe TR, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 June 28;6(6):CD006103Full text
150. Streck JM, Rigotti NA, Livingstone-Banks J, et al. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2024 May 21;5(5):CD001837.Full text Abstract
151. National Institute for Health and Care Excellence. Intravenous fluid therapy in adults in hospital. Clinical guideline CG174. May 2017 [internet publication]Full text
152. National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. Oct 2024 [internet publication].Full text
153. Davison SN. Clinical pharmacology considerations in pain management in patients with advanced kidney failure. Clin J Am Soc Nephrol. 2019 Jun 7;14(6):917-31Full text Abstract
154. UK Kidney Association. Kidney Patient Safety Committee: safe prescribing of opiates in kidney disease. Nov 2020 [internet publication].Full text
155. National Institute for Health and Care Excellence. Pyelonephritis (acute): antimicrobial prescribing. October 2018 [internet publication]Full text
156. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011 Apr;21(2):69-72 Abstract
157. National Institute for Health and Care Excellence. Hypertension in adults. Nov 2023 [internet publication].Full text
158. Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020 Sep 15;142(11):1028-39.Full text Abstract
159. Hogervorst VM, Buurman BM, De Jonghe A, et al. Emergency department management of older people living with frailty: a guide for emergency practitioners. Emerg Med J. 2021 Sep;38(9):724-9 Abstract
160. British Geriatric Society, Centre for Perioperative Care. Guideline for the care of people living with frailty undergoing elective and emergency surgery that encompasses the whole perioperative pathway. Sep 2021 [internet publication].Full text
161. NHS England. Toolkit for general practice in supporting older people living with frailty. March 2017 [internet publication]Full text
162. British Geriatrics Society (BGS), Getting It Right First Time (GIRFT). Six steps to better care for older people in acute hospitals. Jul 2023 [internet publication].Full text
163. Rockwood K; British Geriatrics Society. Silver book II: frailty. February 2021 [internet publication]Full text
164. Falk Erhag H, Guðnadóttir G, Alfredsson J, et al. The association between the clinical frailty scale and adverse health outcomes in older adults in acute clinical settings: a systematic review of the literature. Clin Interv Aging. 2023 Feb;18:249-61.Full text Abstract
165. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 Apr;105(4s):S117-S314.Full text Abstract
166. Conroy SP, Bardsley M, Smith P, et al. Comprehensive geriatric assessment for frail older people in acute hospitals: the HoW-CGA mixed-methods study. Health Services and Delivery Research. 2019 April:7(15)Full text
167. Quinn TJ, Mooijaart SP, Gallacher K, et al. Acute care assessment of older adults living with frailty. BMJ. 2019 Jan 31;364:l13 Abstract
168. Joint British Diabetes Societies for Inpatient Care. The management of diabetic ketoacidosis in adults. Mar 2023 [internet publication].Full text
169. Joint British Diabetes Societies for Inpatient Care. The management of the hyperosmolar hyperglycaemic state (HHS) in adults. Feb 2022 [internet publication].Full text
170. Chowdhury TA, Cheston H, Claydon A. Managing adults with diabetes in hospital during an acute illness. BMJ. 2017 Jun 22;357:j2551 Abstract
171. Joint British Diabetes Societies for Inpatient Care. Self-management of diabetes in hospital. Feb 2023 [internet publication].Full text
172. Joint British Diabetes Societies for Inpatient Care. Glycaemic management during enteral feeding for people with diabetes in hospital. Apr 2024 [internet publication].Full text
173. Joint British Diabetes Societies for inpatient care. The use of variable rate intravenous insulin infusion (VRIII) in medical inpatients. 2014 [internet publication]Full text
174. Joint British Diabetes Societies for Inpatient Care. A good inpatient diabetes service. Jul 2019 [internet publication].Full text
175. Centre for Perioperative Care. Guideline for perioperative care for people with diabetes mellitus undergoing elective and emergency surgery. Dec 2022 [internet publication].Full text
176. Pasquel FJ, Lansang MC, Dhatariya K, et al. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021 Mar;9(3):174-88.Full text Abstract
177. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness. March 2020 [internet publication]Full text
178. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Sep;38(9):1687-93Full text Abstract
179. UK Kidney Association. UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease. April 2023 [internet publication].Full text
180. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023 Jan 12;388(2):117-27.Full text Abstract
181. Natale P, Tunnicliffe DJ, Toyama T, et al. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588.Full text Abstract
182. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis. April 2016 [internet publication]Full text
183. Primary Care Diabetes Society. How to advise on sick day rules. Apr 2020 [internet publication]Full text
184. TREND™Diabetes. Type 2 diabetes: What to do when you are ill. Dec 2022 [internet publication].Full text
185. American Diabetes Association Professional Practice Committee. 16. Diabetes care in the hospital: standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S295-306.Full text Abstract
186. Joint British Diabetes Societies for Inpatient Care. The use of variable rate intravenous insulin infusion (VRIII) in medical inpatients. Oct 2014 [internet publication].Full text
187. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. Aug 2022 [internet publication].Full text
188. Joint British Diabetes Societies for Inpatient Care. Inpatient care of the frail older adult with diabetes. Feb 2023 [internet publication].Full text
189. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67Full text Abstract
190. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97.Full text Abstract
191. Marik PE, Preiser JC. Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis. Chest. 2010 Mar;137(3):544-51Full text Abstract
192. Pasquel FJ, Lansang MC, Dhatariya K, et al. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021 Mar;9(3):174-88Full text Abstract
193. Rehman A, Setter SM, Vue MH. Drug-induced glucose alterations part 2: drug-Induced hyperglycemia. Diabetes Spect. 2011 Nov;24(4):234-8Full text
194. NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2019. Nov 2020 [internet publication]Full text
195. Joint British Diabetes Societies for Inpatient Care. The hospital management of hypoglycaemia in adults with diabetes mellitus. Jan 2023 [internet publication].Full text
196. TREND Diabetes. End of life guidance for diabetes care. November 2021 [internet publication]Full text
197. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. October 2019 [internet publication]Full text
Use of this content is subject to our disclaimer